Table 2.

Additional Ongoing Clinical Trials Evaluating New Anti-CD19 CAR T-cell Products in Patients With CLL

Product Administered	Modification of the CAR Product	NCT Number
SYNCAR-001 + STK-009	Administration of anti-CD19 CAR T cells expressing a mutated IL-2-Rβ plus a half-life extended pegylated IL-2 (STK-009)	NCT05665062
HuCART19-IL18	Fourth-generation 4-1BB CAR T product secreting IL-18	NCT04684563
CD19-CD34t metabolically programmed CAR T cells	Ameliorated purification of the CAR T-cell product via CD34 selection by adding a CD34 tag to the CAR construct; T cells exposed to priming conditions leading to a metabolically enhanced CAR T-cell product akin to a Th1/17 hybrid cell	NCT05702853
CAR19T2	Anti-CD19 CAR T cells incorporating CD28 and TLR2 costimulatory domains	NCT05613348
SAGAN	Anti-CD19 CAR T cells with CD28 and 4-1BB as costimulatory domains	NCT01853631
TBI-2001	Anti-CD19 CAR T cells including costimulatory sequences that lead to the activation of cytokine-related JAK/STAT signaling pathways.	NCT05963217
MB-CART19.1	Anti-CD19 CAR with CD4/CD8 enriched T cells	NCT03853616
CD19 CAR T cells	Anti-CD19 CAR T cells with CD28 and 4-1BB as costimulatory domains	NCT03676504

CAR = chimeric antigen receptor; CLL = chronic lymphocytic leukemia; NCT = National Clinical Trial number.